We then analyzed the available data and provide here several lines of evidence for the involvement of CCR8 in tumor progression in human CRC: 1) CCR8 is downregulated in metastatic tumors compared with non-metastatic tumors in the TCGA cohort (Figure 4D); 2) patients with germline mutations in CCR8 have lower survival rates, albeit not significant (P = 0.069; Figure 4E); 3) expression of CCR8 in the TCGA cohort was significantly associated with good prognosis. The gene discussed is CCR8; the disease is colorectal carcinoma.